What is the debt of Cyclopharm this year?
Cyclopharm has a debt level of -12.28 AUD this year.
Cyclopharm Debt 2025
Cyclopharm Debt
-12.28 AUD
Ticker
CYC.AX
ISIN
AU000000CYC5
In 2025, Cyclopharm's total debt was -12.28 AUD, a 63.78% change from the -7.5 AUD total debt recorded in the previous year.
Cyclopharm Aktienanalyse
What does Cyclopharm do?
Cyclopharm Ltd is an Australian company that was founded in 1986 and has since been developing innovative medical solutions. The company operates in the field of nuclear medicine and focuses on providing diagnostic and therapeutic products and services. The history of Cyclopharm Ltd began with the development of the Technetium-99m generator, an instrument for generating radioisotopes that can be used in medical imaging. Since then, the company has expanded its offerings and now offers a wide range of products and services. Cyclopharm Ltd's business model is based on research and development of new solutions based on the needs of the medical community and patients. The company works closely with doctors, scientists, and other experts to ensure that its products and services meet the highest standards. Cyclopharm Ltd is divided into various divisions to coordinate and optimize its activities. These include diagnostics, therapy, research and development, as well as sales and marketing. Each division works closely with the others to ensure that the company achieves its goals and provides optimal customer care. Some of Cyclopharm Ltd's most well-known products include the Technetium-99m generator and the radiopharmaceutical Technegas. Technegas is a gas used for lung imaging and plays an important role in diagnosing lung problems. The radiopharmaceutical is produced using the Technetium-99m generator and is an important addition to medical imaging. In addition, Cyclopharm Ltd also develops therapeutic solutions that can be used to treat cancer and other diseases. These include radiopharmaceuticals used in radiation therapy, as well as other solutions tailored to the individual needs of patients. Cyclopharm Ltd is also actively working on improving and expanding its products and services. The company invests in research and development to develop innovative solutions that can improve medical imaging and therapy. Additionally, the company works closely with its customers to better understand their needs and offer them tailored solutions. Overall, Cyclopharm Ltd is an innovative and goal-oriented company that focuses on providing diagnostic and therapeutic solutions in the field of nuclear medicine. The company has a long history of leadership in this field and will continue to be at the forefront of developing solutions that improve the lives of patients and medical professionals. Cyclopharm ist eines der beliebtesten Unternehmen auf Eulerpool.com.Debt Details
Understanding Cyclopharm's Debt Structure
Cyclopharm's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Year-to-Year Comparison
Analyzing Cyclopharm's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Impact on Investments
Investors pay close attention to Cyclopharm’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Interpreting Debt Fluctuations
Shifts in Cyclopharm’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
Frequently Asked Questions about Cyclopharm stock
What was the debt of Cyclopharm compared to the previous year?
The debt of Cyclopharm has increased by 63.78% compared to the previous year increased.
What are the consequences of high debt for investors in Cyclopharm?
High debt can pose a risk for investors of Cyclopharm, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.
What are the consequences of low debt for investors of Cyclopharm?
Low debt means that Cyclopharm has a strong financial position and is able to fulfill its obligations without overburdening its finances.
How does an increase in debt from Cyclopharm affect the company?
An increase in debt of Cyclopharm can adversely affect the financial condition of the company and result in a higher burden on its finances.
How does a reduction of debt of Cyclopharm affect the company?
A reduction in debt of Cyclopharm can strengthen the company's financial position and improve its ability to meet its financial obligations.
What are some factors that influence the debt of Cyclopharm?
Some factors that can influence the debt of Cyclopharm include investments, acquisitions, operating costs, and revenue development.
Why are the debts of Cyclopharm so important for investors?
The debts of Cyclopharm are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.
What strategic measures can Cyclopharm take to change the debt?
To change the debt, Cyclopharm can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.
How much dividend does Cyclopharm pay?
Over the past 12 months, Cyclopharm paid a dividend of 0.01 AUD . This corresponds to a dividend yield of about 1.15 %. For the coming 12 months, Cyclopharm is expected to pay a dividend of -0.03 AUD.
What is the dividend yield of Cyclopharm?
The current dividend yield of Cyclopharm is 1.15 %.
When does Cyclopharm pay dividends?
Cyclopharm pays a quarterly dividend. This is distributed in the months of May, October, April, October.
How secure is the dividend of Cyclopharm?
Cyclopharm paid dividends every year for the past 1 years.
What is the dividend of Cyclopharm?
For the upcoming 12 months, dividends amounting to -0.03 AUD are expected. This corresponds to a dividend yield of -3.62 %.
In which sector is Cyclopharm located?
Cyclopharm is assigned to the 'Health' sector.
Wann musste ich die Aktien von Cyclopharm kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Cyclopharm from 9/11/2023 amounting to 0.005 AUD, you needed to have the stock in your portfolio before the ex-date on 9/1/2023.
When did Cyclopharm pay the last dividend?
The last dividend was paid out on 9/11/2023.
What was the dividend of Cyclopharm in the year 2024?
In the year 2024, Cyclopharm distributed 0.01 AUD as dividends.
In which currency does Cyclopharm pay out the dividend?
The dividends of Cyclopharm are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Cyclopharm
Our stock analysis for Cyclopharm Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cyclopharm Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
